Hemostemix finally get its control over intellectual propertAll the intellectual property, including all historical data from Hemostemix Israel, the phase II clinical trial data of HS 12-01, and randomization tables, which are required to analyze the North American and South African ACP-01 clinical trial data, is finally returned to its home.